Clinical Science
Peer-reviewed research, clinical trial results, and evidence-based analysis on GLP-1 receptor agonists, muscle preservation, and metabolic health.
Investigation
The Muscle Crisis: 25–40% of GLP-1 Weight Loss Is Lean Mass, Not Fat
Clinical trial data reveals that a quarter to nearly half of weight lost on GLP-1 medications is lean muscle mass—not adipose tissue. The crisis the industry hides.
Clinical Trial
SURMOUNT-5: Tirzepatide Outperforms Semaglutide in First Head-to-Head Trial
The long-awaited direct comparison showed tirzepatide producing 20.2% body weight loss versus 13.7% for semaglutide over 72 weeks.
Featured Report
The Truth About GLP-1s: 5 Things Your Provider Isn't Telling You
Over 40 million Americans have been prescribed a GLP-1 medication. Most were never told the five things in this report.
Physician-Led Program · Lion MD
Compounded Tirzepatide
Dual-action GLP-1/GIP. Enhanced appetite control + metabolic improvement.
From $139/mo
Get Started →